Overview

Antipsychotics and Risk of Hyperglycemic Emergencies

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs.
Details
Lead Sponsor:
Canadian Network for Observational Drug Effect Studies, CNODES
Collaborators:
Canadian Institutes of Health Research (CIHR)
Drug Safety and Effectiveness Network, Canada
Treatments:
Antipsychotic Agents
Aripiprazole
Chlormezanone
Chlorpromazine
Chlorprothixene
Clopenthixol
Clozapine
Flupenthixol
Flupenthixol decanoate
Fluphenazine
Fluphenazine depot
Fluphenazine enanthate
Fluspirilene
Haloperidol
Haloperidol decanoate
Loxapine
Mesoridazine
Methotrimeprazine
Olanzapine
Paliperidone Palmitate
Perphenazine
Pimozide
Quetiapine Fumarate
Risperidone
Tetrabenazine
Thioridazine
Thiothixene
Trifluoperazine
Ziprasidone